NASDAQ: MRKRMarker Therapeutics Inc Stock
$4.37-0.03 (-0.68%)
Updated Apr 25, 2024
MRKR Price
$4.37
Fair Value Price
N/A
Market Cap
$38.86M
52 Week Low
$0.76
52 Week High
$9.68
P/E
-4.64x
P/B
2.77x
P/S
14.63x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.31M
Earnings
-$8.24M
Gross Margin
100%
Operating Margin
-248.65%
Profit Margin
-248.8%
Debt to Equity
0.22
Operating Cash Flow
-$16M
Beta
1.01
Next Earnings
Jun 5, 2024
Ex-Dividend
N/A
Next Dividend
N/A
MRKR Overview
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MRKR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MRKR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MRKR is good value based on its book value relative to its share price (2.77x), compared to the US Biotechnology industry average (5.8x)
P/B vs Industry Valuation
MRKR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MRKR due diligence checks available for Premium users.
Be the first to know about important MRKR news, forecast changes, insider trades & much more!
MRKR News
Valuation
MRKR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.64x
Industry
15.41x
Market
40.97x
MRKR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.77x
Industry
5.8x
MRKR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MRKR's financial health
Profit margin
Revenue
$1.1M
Net Income
-$2.8M
Profit Margin
-265.3%
MRKR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MRKR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$17.1M
Liabilities
$3.1M
Debt to equity
0.22
MRKR's short-term assets ($17.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MRKR's short-term assets ($17.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MRKR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MRKR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.4M
Investing
$0.0
Financing
$5.1k
MRKR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MRKR vs Biotech Stocks
Marker Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.